Solid Biosciences (NASDAQ: SLDB) — Perfil da empresa, notícias e dados financeiros
ASA Gold and Precious Metals is an investment fund focused on gold and precious metals through a diversified portfolio.
Solid Biosciences
Solid Biosciences (NASDAQ:SLDB) focuses on developing therapies for Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. With a dedication to improving the lives of patients affected by these conditions, the company's operations span research, development, and advocacy within the neuromuscular disease community. Solid Biosciences is driven by a commitment to advancing scientific research and therapy options for those facing DMD, aiming to address the unmet medical needs of the Duchenne community through innovative solutions and partnerships. Their objectives revolve around progressing their lead gene therapy candidate through clinical trials and ultimately delivering transformative treatments to patients and their families.
Resumo
Operações
Produtos e/ou serviços de Solid Biosciences
- Sarepta Therapeutics, Inc. acquired the global rights to SGT-001, a gene therapy for Duchenne Muscular Dystrophy, aiming to address the underlying genetic cause and promote dystrophin production.
- Development of novel manufacturing processes for adeno-associated virus (AAV) vectors, enhancing the scalability and efficiency of gene therapy production.
- Research into next-generation gene therapy candidates, focusing on innovative approaches for treating Duchenne Muscular Dystrophy and other genetic diseases.
- Collaboration with academic and industry partners to discover and develop targeted therapies for muscular dystrophies, leveraging expertise in muscle biology.
- Implementation of patient-centric programs to support the Duchenne Muscular Dystrophy community, offering resources, education, and access to new therapies.
- Engagement in scientific forums and conferences to share findings, fostering collaboration and driving forward the research in gene therapy and muscular dystrophy treatment.
equipe executiva do Solid Biosciences
- Ian F. SmithExecutive Chair
- Alexander G. CumboPresident, CEO & Director
- Ilan GanotCo-founder, Strategic Advisor to the CEO & Director
- David Tyronne Howton Jr.COO & Secretary
- Gabriel BrooksChief Medical Officer
- Annie GanotCo-Founder & VP of Patient Advocacy
- Kevin TanCFO & Treasurer
- Paul HerzichChief Technology Officer
- Nicole AndersonSenior Director of Investor Relations & Corporate Communications
- Jessie HanrahanChief Regulatory & Preclinical Operations Officer
Principais indicadores financeiros
Resultados divulgados pela Solid Biosciences , em USD.
- Cap. de mercado
- 663,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -179,2 mi | -174,3 mi | |
| 0 | -129,7 mi | -124,7 mi | |
| 0 | -104,3 mi | -96 mi | |
| 8,1 mi | -106,5 mi | -86 mi |